We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Most high-risk neuroblastoma respond to therapy by complete clinical remission, but frequently relapse as therapy-resistant disease. Our lab aims to elucidate this enigmatic process and to devise new treatment options to prevent resistance and relapse.
We have identified that neuroblastoma includes lineage-committed adrenergic (ADRN) cells and a minor fraction of undifferentiated mesenchymal (MES) tumor cells. These cell states can spontaneously transdifferentiate and have been extensively characterized for their transcriptional states, chromatin landscapes and lineage transcription factor networks. Importantly, MES cells are resistant to a wide variety of drugs used in the clinical management of neuroblastoma. We have developed an in vivo relapse model and found that combinations of MES- and ADRN-specific drugs delays the onset of relapses. I will discuss how normal development and tumour cell heterogeneity provide a framework to understand resistance and the potential for relapse development.
Short CV: Johan van Nes studied Biology and obtained a PhD from Utrecht University for his work on mouse developmental genetics. He leads a research group that studies the biology of relapse development in the childhood tumour neuroblastoma (Amsterdam UMC, location AMC, Amsterdam). His research focuses on fundamental insights in intra-tumour heterogeneity and tumour cell plasticity to identify new therapeutic combinations to combat relapses.
Host: Miguel Segura / Carlos Jiménez, Group of Translational Research in Child and Adolescent Cancer. Vall d'Hebron Institut of Research (VHIR). Hospital Universitari Vall d'Hebron
Format: Face-to-face and online Streaming link: click here
LLoc: Sala d'Actes de la planta baixa de l'HG
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to email@example.com, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.